Breast Cancer

Race demonstrated differences in overall survival outcomes, but not for three-year recurrence-free survival in patients with HR-positive, HER2-negative breast cancer, according to data.

The combination of Keytruda to neoadjuvant chemotherapy, followed by Keytruda in combination with endocrine therapy improved pathologic response rates for patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer.

Research is underway on the immune-stimulating antibody conjugate BDC-1001’s effectiveness against HER2-positive cancers when combined with Perjeta, according to data presented at SABCS.

Patients with HR-positive, HER2-negative breast cancer tended to have longer health-related quality of life and improved outcomes with Truqap plus Faslodex, research showed.

The use of artificial intelligence to detect sentinel lymph nodes in patients with breast cancer may be able to save time and reduce costs as compared with immunohistochemistry.

Every holiday season, one song starts to play in my head even if I do not hear it on the radio: “All I Want for Christmas Is My Two Front Teeth.”

Patients with HR-positive HER2-negative advanced breast cancer, including elderly patients, derived a progression-free and overall survival benefit with Kisqali plus endocrine therapy compared with placebo plus endocrine therapy.

Here's what you can be thankful for...

I used my tools as a psychotherapist after being faced with my own cancer diagnosis.

Zotatifin plus Faslodex and Verzenio was granted as a Fast Track Designation for the treatment of ER-positive, HER2-negative advanced or metastatic breast cancer.

The Truqap-Faslodex treatment combination offers “more options” for some patients with HR-positive, HER2-negative breast cancer, an expert told CURE®.

As Shannen Doherty revealed her cancer diagnoses and upcoming podcast and a woman with breast cancer completed her bucket list, here is what’s happening in the oncology space this week.

Peer- and self-evaluated techniques are being incorporated to improve the sexual health of women with breast cancer.

If metastatic breast cancer no longer responds to a given therapy, finding out what targetable mutations a patient has may guide the next steps for treatment, an expert said.

Since your diagnosis and treatments, how many life direction changes have you made?

The Food and Drug Administration approved six new cancer therapies in November 2023.

Being thankful for cancer seems like an odd concept to grasp.

Sara M. Tolaney, MD, MPH explains that treatment decisions for metastatic breast cancer are based on the current biopsy showing receptor status, but prior biopsies over the full course of disease are considered as well, particularly for HER2 targeted therapies which may work even if HER2 low expression occurred years earlier.

My experience with a cancer biopsy.

A recent study evaluated the low rate and racial disparities in utilization of palliative care.

While many parts of my cancer experience were extremely difficult, I tried to embrace it — and accept help when needed.

Losing someone to cancer never gets easier.

Truqap (capivasertib) with fulvestrant has been approved for the treatment of adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, the FDA announced.

Sara M. Tolaney, MD, MPH, states that all breast cancers should be tested for estrogen, progesterone, and HER2 receptors; HER2 testing involves an immunohistochemistry stain to quantify protein levels, with 3+ indicating HER2+ disease, 0 indicating HER2- disease, and 1-2+ levels needing additional FISH testing to clarify HER2 status.

Sara M. Tolaney, MD, MPH, introduces the role of HER2 as a breast cancer cell growth receptor and explains HER2-positive versus HER2-negative.

Where I grew up, cancer was not openly discussed.

Patients who had low levels of vitamin D before starting chemotherapy tended to have higher rates of chemotherapy-induced peripheral neuropathy, but more research is needed in this field.

After receiving a cancer diagnosis, it stays with you 24/7.